News Background

Oxford, UK – 09 October 2014. OGT, the molecular genetics company, has won the Best Medtech Dealmaker award for the second year in a row at the Oxford Bioscience Network (OBN) awards held on Thursday 2 October. The award recognises OGT’s acquisition of Cambridge-based CytoCell® Limited (CytoCell), a leading provider of DNA technology for the detection of gene rearrangements related to inherited genetic disease and cancer.

The acquisition, which took place in March 2014, enables OGT to increase its genomic medicine offering by enabling entry into the complementary and rapidly growing market for fluorescence in situ hybridisation (FISH) products. Through leveraging its dedicated sales and support infrastructure, OGT now sells CytoCell products directly in North America, providing enhanced service and promotional capabilities.

By acquiring Cytocell, OGT has been able to combine the two companies’ expertise and reach. In addition, access to CytoCell’s proprietary collection of 34,000 Bacterial Artificial Chromosome (BAC) clones provides a unique source of potential products. OGT is already utilising its expanded resources and cross portfolio synergies to develop and promote a number of new products.

Dr Jon Rees, CEO of OBN commented, “The quality of nominees continues to rise year on year and compiling a shortlist and picking winners gets harder. The award of Best Medtech Dealmaker to Oxford Gene Technology reflects what has been a highly successful move for both OGT and CytoCell. To win this award twice in consecutive years makes a real statement about OGT’s ambition, strong business model and strategy.”

Tim Hall, CFO of OGT said, “The acquisition of CytoCell represents our commitment to becoming a global leader in genomic medicine. We are very grateful to the OBN for recognising the opportunity and the value of the deal. CytoCell’s innovative DNA technology and strong brand has added to our portfolio of class-leading genomic technologies, and we are already seeing the benefits.”

The CytoCell acquisition has significantly increased OGT’s sales of genomic products which grew by over 75% in the year ending 30 September 2014.


About OGT

OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.


For more information on the Company, please visit our website at


CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.


About Sysmex Corporation

Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.


For more information about Sysmex Corporation and its affiliate companies, please visit

Related content

  • Share

You might also be interested in

Global Reach

OGT's CytoCell portfolio available via Sysmex in China and Spain

06 Jul 2020

Addition of direct-sales territories follows successes across Europe and APAC and provides customers with enhanced local sales and support services.

Array Scientist Loads Sample

NHS study confirms higher reporting rate for OGT's CytoSure v3 array

22 Jul 2020

Paper published in npj Genomic Medicine demonstrates identification of more reportable CNVs with CytoSure® v3 vs traditional array design.

Cancer Cell

OGT expands NGS cancer panel offering

03 Nov 2020

Launch of two NGS panels enables comprehensive detection of genetic abnormalities involved in breast and ovarian cancer, and myeloid disorders.

All News
CTA Icon

Stay up-to-date with the latest news from OGT, including new products, support resources, and our DNA Dispatch newsletter